PLK1 Inhibition Induces Immunogenic Cell Death and Enhances Immunity against NSCLC

PLK1 inhibitors were shown, in vitro and in vivo, to possess inhibitory activities against non-small cell lung cancer (NSCLC), and such inhibition has been proven by clinical trials. However, it remains unclear whether and how the immune microenvironment is associated with the action. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jie, Yang, Qifan, Lu, Lisen, Tuo, Zhan, Shou, Zhexing, Cheng, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436107/
https://www.ncbi.nlm.nih.gov/pubmed/34522178
http://dx.doi.org/10.7150/ijms.60135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436107/
https://www.ncbi.nlm.nih.gov/pubmed/34522178
http://dx.doi.org/10.7150/ijms.60135

Ejemplares similares